SR9883 is a novel small-molecule enhancer of α4β2* nicotinic acetylcholine receptor signaling that decreases intravenous nicotine self-administration in rats
These data suggest that SR9883 is useful for investigating behavioral processes regulated by certain α4β2* nAChR stoichiometries. SR9883 and related compounds with favorable drug-like physiochemical and pharmacological properties hold promise as novel treatments of tobacco use disorder.
Authors
- Paul J. Kenny (ORCID: https://orcid.org/0000-0003-2426-3641)
- George Voren
- Kevin M. Braunscheidel
- Michael D. Cameron (ORCID: https://orcid.org/0000-0003-3154-4775)
- Qun Lu (ORCID: https://orcid.org/0000-0002-6211-6565)
- Christie D. Fowler (ORCID: https://orcid.org/0000-0003-2864-2163)
- Theodore M. Kamenecka (ORCID: https://orcid.org/0000-0002-3077-0167)
- Inés Ibáñez-Tallon (ORCID: https://orcid.org/0000-0002-4908-4626)
- Alexander Kuryatov
- Jon Lindstrom
Institutions
- Scripps Research Institute (US)
- Allen Institute for Brain Science (US)
- University of California, Irvine (US)
- University of Pennsylvania (US)
- Rockefeller University (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Frontiers in Molecular Neuroscience
- Published
- 2024-09-05
- DOI
- https://doi.org/10.3389/fnmol.2024.1459098
- Citations
- 3
- Primary Topic
- Nicotinic Acetylcholine Receptors Study
- Type
- article
- Field-Weighted Citation Impact
- 0.70